)
)
)
Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Cereno's pipeline includes an HDACi portfolio with two drug candidates in clinical phase – CS1 in PAH and CS014 in PH-ILD/IPF. CS1 completed Phase 2a trial and submitted Phase 2b protocol to FDA on Nov 7th 2025 (expecting greenlight on 8th Dec), our novel HDACi CS014 completed Phase 1 and released Topline results in July 2025. Preparations ongoing to initiate a Phase 2 program in PH-ILD/IPF.
Preclinical asset- CS585, novel prostacyclin (IP) receptor agonist- demonstrated potential to significantly improve disease mechanisms relevant to cardiovascular disease.
Near term upcoming milestone:
CS1 Phase 2b initiation - H1 2026
CS014 Phase 2 initiation - H2 2026
Address
GöteborgSweden
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)